Aclaris Therapeutics (ACRS) Set to Announce Quarterly Earnings on Thursday

Key Points

• Aclaris Therapeutics is expected to report Q3 2026 results before Thursday’s market open. Analysts forecast a loss of $0.16 per share on $1.23 million in revenue; the earnings call is scheduled for Friday, November 6.
• The company reported positive Phase 1b proof-of-concept results for ATI-052 in atopic dermatitis and asthma, supporting its immuno-inflammatory pipeline. Analysts remain broadly positive, with a consensus “Buy” rating and an $11 price target.
• Aclaris priced a roughly $50 million stock and pre-funded warrant offering to fund development and strengthen its balance sheet, but the below-market pricing and potential share dilution pressured the stock.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) is expected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.16) per share and revenue of $1.23 million for the quarter. Parties may visit the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 6, 2026 at 12:30 PM ET.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.16) by $0.01. Aclaris Therapeutics had a negative net margin of 921.50% and a negative return on equity of 61.65%. The firm had revenue of $1.63 million during the quarter, compared to the consensus estimate of $1.38 million. On average, analysts expect Aclaris Therapeutics to post ($0.62) EPS for the current fiscal year and ($0.64) EPS for the next fiscal year.

Aclaris Therapeutics Price Performance

ACRS stock opened at $3.96 on Thursday. The firm has a market cap of $553.69 million, a price-to-earnings ratio of -6.83 and a beta of 0.87. Aclaris Therapeutics has a 1-year low of $2.10 and a 1-year high of $6.60. The firm has a fifty day moving average price of $4.98 and a two-hundred day moving average price of $4.50.

Key Headlines Impacting Aclaris Therapeutics

Here are the key news stories impacting Aclaris Therapeutics this week:

• Positive Sentiment: Aclaris reported positive Phase 1b proof-of-concept results for ATI-052, its anti-TSLP/IL-4Rα bispecific candidate, in atopic dermatitis and asthma. The data provide early clinical support for the company’s immuno-inflammatory pipeline and could improve the program’s development prospects. Aclaris ATI-052 Phase 1b results
• Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and assigned a $16 price target, implying substantial upside if Aclaris successfully advances ATI-052 and its broader pipeline. HC Wainwright rating
• Neutral Sentiment: Wedbush maintained an “outperform” rating but reduced its price target to $8 from $10. The target remains well above the current trading level, but the cut suggests more cautious near-term assumptions. Wedbush Aclaris price target
• Negative Sentiment: Aclaris priced a roughly $50 million underwritten offering consisting of 7.8 million common shares at $3.50 each and pre-funded warrants representing another 6.5 million shares. The financing strengthens the balance sheet and funds development, but the large potential increase in shares outstanding—and pricing below the market—dilutes existing shareholders and appears to be the main reason the stock declined despite the positive trial news. Aclaris $50 million offering

Wall Street Analyst Weigh In

ACRS has been the subject of a number of recent research reports. Wall Street Zen upgraded Aclaris Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, October 24th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Aclaris Therapeutics in a research report on Monday, September 21st. Canaccord Genuity Group initiated coverage on shares of Aclaris Therapeutics in a research note on Tuesday, September 1st. They issued a "buy" rating and a $10.00 price target on the stock. Wedbush reduced their price objective on Aclaris Therapeutics from $10.00 to $8.00 and set an "outperform" rating for the company in a research report on Wednesday. Finally, HC Wainwright reissued a "buy" rating and issued a $16.00 price objective on shares of Aclaris Therapeutics in a report on Wednesday. Three analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Aclaris Therapeutics has a consensus rating of "Buy" and a consensus target price of $11.00.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc NASDAQ: ACRS is a clinical-stage biopharmaceutical company focused on developing therapies for immune-inflammatory diseases. The company's research programs are designed to address conditions in areas such as rheumatology, dermatology and other inflammatory disorders.

Aclaris' lead investigational product is zunsemetinib (ATI-450), an oral small-molecule therapy being evaluated for inflammatory diseases. The company has also developed additional investigational programs, including selective kinase inhibitors intended for potential use in dermatologic and immune-mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.